Brief: Ascletis To Submit IND To U.S. FDA For ASC37 Oral Tablets In 2nd Qtr Of 2026
30/11/2025 10:25
Nov 30 (Reuters) - Ascletis Pharma Inc 1672.HK: EXPECTS TO SUBMIT INVESTIGATIONAL NEW DRUG APPLICATION (IND)TO U.S. FDA FOR ASC37 ORAL TABLETS IN SECOND QUARTER OF 2026 Source text Further company coverage: 1672.HK (Reporting by Hong Kong newsroom) ((donny.kwok@thomsonreuters.com; +852 3462 7745;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management